Definium Therapeutics (DFTX) Non Operating Income (2019 - 2026)
Definium Therapeutics (DFTX) reported Non Operating Income of -$17.9 million for Q1 2026, down 302.91% year-over-year from $8.8 million in Q1 2025, and down 525.54% on a QoQ basis from -$2.9 million in Q4 2025.
Definium Therapeutics (DFTX) has 7 years of Non Operating Income data on file, last reported at -$17.9 million in Q1 2026.
- Quarterly Non Operating Income fell 302.91% year-over-year to -$17.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.2 million (down 221.88% YoY) and the FY2025 annual result came in at -$17.5 million, down 267.08% from the prior year.
- Non Operating Income retreated to -$17.9 million in Q1 2026 per DFTX's latest filing, from -$2.9 million in the prior quarter.
- Across five years, Non Operating Income topped out at $18.6 million in Q2 2024 and bottomed at -$32.2 million in Q1 2024.
- The 5-year median for Non Operating Income is -$14000.0 (2022), against an average of -$1.9 million.
- The widest annual swing landed in 2023, when Non Operating Income slumped 7420.37%; it then soared 34351.85% in 2024.
- Tracing DFTX's Non Operating Income over 5 years: stood at $9.0 million in 2022, then slumped by 118.44% to -$1.7 million in 2023, then tumbled by 37.37% to -$2.3 million in 2024, then dropped by 25.41% to -$2.9 million in 2025, then sank by 525.54% to -$17.9 million in 2026.
- Per Business Quant, the three latest DFTX Non Operating Income figures stand at -$17.9 million (Q1 2026), -$2.9 million (Q4 2025), and -$21.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | -17.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.88 Mn |
| Dec 31, 2025 | -2.86 Mn |
| Sep 30, 2025 | -21.60 Mn |
| Jun 30, 2025 | -1.84 Mn |
| Mar 31, 2025 | 8.81 Mn |
| Dec 31, 2024 | -2.28 Mn |
| Sep 30, 2024 | 11.11 Mn |
| Jun 30, 2024 | 18.60 Mn |
| Mar 31, 2024 | -32.20 Mn |
| Dec 31, 2023 | -1.66 Mn |
| Sep 30, 2023 | 3.69 Mn |
| Jun 30, 2023 | 54,000.00 |
| Mar 31, 2023 | -3.95 Mn |
| Dec 31, 2022 | 9.00 Mn |
| Sep 30, 2022 | 498,000.00 |
| Jun 30, 2022 | -14,000.00 |
| Mar 31, 2022 | 54,000.00 |
| Dec 31, 2021 | -428,000.00 |
| Sep 30, 2021 | 31,000.00 |
| Jun 30, 2021 | -32,000.00 |
| Mar 31, 2021 | 89,000.00 |
| Dec 31, 2019 | 28,000.00 |